Skip to main content

Table 3 Drug resistance conferring mutations from the current study

From: Seroprevalence and genotypic characterization of HBV among low risk voluntary blood donors in Nairobi, Kenya

Accession number Mutations Drug resisted HBsAg sero status
MT185643 Y126H Adefovir dipivoxil(ADV) Negative
M129L Lamivudine
V163I Lamivudine
MT185642 Y126H Adefovir dipivoxil(ADV) Negative
M129L Lamivudine
V163I Lamivudine
MT185644 Y126H Adefovir dipivoxil(ADV) Positive
M129L Lamivudine
V163I Lamivudine
MT185645 Y126H Adefovir dipivoxil(ADV) Negative
M129L Lamivudine
V163I Lamivudine
S202G Entecavir & Lamivudine
MT185646 Y126H Adefovir dipivoxil(ADV) Negative
M129L Lamivudine
V163I Lamivudine
MT185647 Y126H Adefovir dipivoxil(ADV) Negative
M129L Lamivudine
V163I Lamivudine
MT185648 M129L Lamivudine Negative
V163I Lamivudine
MT185649 M129L Lamivudine Positive
V163I Lamivudine
MT185650 M129L Lamivudine Negative
V163I, Lamivudine
A181T Lamivudine (zeffix), Adefovir(Hepsera), Telbivudine(Tyzeka and Sebivo)
  1. These mutations were identified using two online tools Geno2Pheno HBV database (HBVdb) (https://hbv.geno2pheno.org/) and HBVseq program from HIV Stanford database (https://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html). The mutations are listed for each of the sample where they occurred